Eli Lil­ly's much-ma­ligned Branch­burg plant earns a fed­er­al sub­poe­na amid whistle­blow­er claims tied to Covid-19 work

With Eli Lil­ly’s work on Covid-19 an­ti­bod­ies fac­ing mul­ti­ple set­backs at the FDA and state lev­el, the plant re­spon­si­ble for pro­duc­ing the drugs has seen a flush of em­ploy­ee com­plaints al­leg­ing fudged doc­u­ments and poor con­di­tions. Now, the De­part­ment of Jus­tice is get­ting in­volved and wants to see Lil­ly’s pa­per­work.

The DOJ hit Lil­ly with a sub­poe­na re­quest­ing ad­di­tion­al doc­u­men­ta­tion on its work at a Branch­burg, NJ plant, the In­di­anapo­lis drug­mak­er said in an SEC fil­ing. The scope of the DOJ’s in­ves­ti­ga­tion is un­clear, but in ear­ly May, Reuters re­port­ed that the com­pa­ny’s em­ploy­ees ac­cused an ex­ec­u­tive of al­ter­ing doc­u­ments re­quired by reg­u­la­tors to down­play qual­i­ty con­trol prob­lems at the plant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER